A residual cancer burden after neoadjuvant therapy (NAT) for breast cancer (BC) is associated with worse treatment outcomes compared to patients who achieved pathologic complete remission. This single-institutional retrospective study of 767 consecutive patients, including 468 patients with assessable residual cancer burden (aRCB) after NAT, with a median follow-up of 36 months, evaluated the biomarkers assessed before NAT from a biopsy and after NAT from a surgical specimen, their dynamics, and effect on long-term outcomes in specific breast cancer subtypes.

The paper concludes that this real-world data of a consecutive cohort confirmed the importance of biomarker assessments in patients with aRCB, and the need to consider specific BC subtypes when interpreting their influence on prognosis.

Read full article here:  https://pubmed.ncbi.nlm.nih.gov/35885644/